Human Molecular Genetics, 2000, Vol. 9, No. 5 735-744
© 2000 Oxford University Press
Batten disease: evaluation of CLN3 mutations on protein localization and function
Program in Gene Therapy, Departments of 1Internal Medicine and 2Neurology, University of Iowa, Iowa City, IA 52242, USA, 3Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA and 4Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
Juvenile neuronal ceroid lipofuscinosis (JNCL), Batten disease, is an autosomal recessive lysosomal storage disease associated with mutations in CLN3. CLN3 has no known homology to other proteins and a function has not yet been described. The predominant mutation in CLN3 is a 1.02 kb genomic deletion that accounts for nearly 85% of the disease alleles. In this mutation, truncation of the protein by a premature stop codon results in the classical phenotype. Additional missense and nonsense mutations have been described. Some missense substitutions result in a protracted pheno- type, with delays in the onset of classical clinical features, whereas others lead to classical JNCL. In this study, we examined the effect of naturally occurring point mutations on the intracellular localization of CLN3 and their ability to complement the CLN3-deficient yeast, btn1-
. We also examined a putative farnesylation motif thought to be involved in CLN3 trafficking. All of the point mutations, like wild-type CLN3, were highly associated with lysosome-associated membrane protein II in non-neuronal cells and with synaptophysin in neuronal cell lines. In the yeast functional assay, point mutations correlating with a mild phenotype also demonstrated CLN3 activity, whereas the mutations associated with severe disease failed to restore CLN3 function completely. CLN3 with a mutation in the farnesylation motif trafficked normally but was functionally impaired. These data suggest that these clinically relevant point mutations, causative of Batten disease, do not affect protein trafficking but rather exert their effects by impairing protein function.
+ To whom correspondence should be addressed. Tel: +1 319 353 5511; Fax: +1 319 353 5572; Email: beverly-davidson@uiowa.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Codlin and S. E. Mole S. pombe btn1, the orthologue of the Batten disease gene CLN3, is required for vacuole protein sorting of Cpy1p and Golgi exit of Vps10p J. Cell Sci., April 15, 2009; 122(8): 1163 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Eliason, C. S. Stein, Q. Mao, L. Tecedor, S.-L. Ding, D. M. Gaines, and B. L. Davidson A Knock-In Reporter Model of Batten Disease J. Neurosci., September 12, 2007; 27(37): 9826 - 9834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-W. Chang, H. Choi, H.-J. Kim, D.-G. Jo, Y.-J. Jeon, J.-Y. Noh, W. J. Park, and Y.-K. Jung Neuronal vulnerability of CLN3 deletion to calcium-induced cytotoxicity is mediated by calsenilin Hum. Mol. Genet., February 1, 2007; 16(3): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ramirez-Montealegre and D. A. Pearce Defective lysosomal arginine transport in juvenile Batten disease Hum. Mol. Genet., December 1, 2005; 14(23): 3759 - 3773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Gachet, S. Codlin, J. S. Hyams, and S. E. Mole btn1, the Schizosaccharomyces pombe homologue of the human Batten disease gene CLN3, regulates vacuole homeostasis J. Cell Sci., December 1, 2005; 118(23): 5525 - 5536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kyttala, K. Yliannala, P. Schu, A. Jalanko, and J. P. Luzio AP-1 and AP-3 Facilitate Lysosomal Targeting of Batten Disease Protein CLN3 via Its Dileucine Motif J. Biol. Chem., March 18, 2005; 280(11): 10277 - 10283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kim, S. Chattopadhyay, S. Locke, and D. A. Pearce Interaction among Btn1p, Btn2p, and Ist2p Reveals Potential Interplay among the Vacuole, Amino Acid Levels, and Ion Homeostasis in the Yeast Saccharomyces cerevisiae Eukaryot. Cell, February 1, 2005; 4(2): 281 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Luiro, K. Yliannala, L. Ahtiainen, H. Maunu, I. Jarvela, A. Kyttala, and A. Jalanko Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway Hum. Mol. Genet., December 1, 2004; 13(23): 3017 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chattopadhyay, E. Kingsley, A. Serour, T. M. Curran, A. I. Brooks, and D. A. Pearce Altered Gene Expression in the Eye of a Mouse Model for Batten Disease Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 2893 - 2905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Narayan, J. V. Pastor, H. M. Mitchison, and M. J. Bennett CLN3L, a novel protein related to the Batten disease protein, is overexpressed in Cln3-/- mice and in Batten disease Brain, August 1, 2004; 127(8): 1748 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kyttala, G. Ihrke, J. Vesa, M. J. Schell, and J. P. Luzio Two Motifs Target Batten Disease Protein CLN3 to Lysosomes in Transfected Nonneuronal and Neuronal Cells Mol. Biol. Cell, March 1, 2004; 15(3): 1313 - 1323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kim, D. Ramirez-Montealegre, and D. A. Pearce A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease PNAS, December 23, 2003; 100(26): 15458 - 15462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sappington, D. A. Pearce, and D. J. Calkins Optic Nerve Degeneration in a Murine Model of Juvenile Ceroid Lipofuscinosis Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 3725 - 3731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.-A. N. W. Persaud-Sawin, A. VanDongen, and R.-M. N. Boustany Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis Hum. Mol. Genet., September 1, 2002; 11(18): 2129 - 2142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chattopadhyay and D. A. Pearce Interaction with Btn2p Is Required for Localization of Rsg1p: Btn2p-Mediated Changes in Arginine Uptake in Saccharomyces cerevisiae Eukaryot. Cell, August 1, 2002; 1(4): 606 - 612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chattopadhyay, M. Ito, J. D. Cooper, A. I. Brooks, T. M. Curran, J. M. Powers, and D. A. Pearce An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease Hum. Mol. Genet., June 1, 2002; 11(12): 1421 - 1431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Luiro, O. Kopra, M. Lehtovirta, and A. Jalanko CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease Hum. Mol. Genet., September 1, 2001; 10(19): 2123 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bodzioch, C. Aslanidis, M. Kacinski, N. Zhong, K. E. Wisniewski, and G. Schmitz Rapid Detection of the Two Most Common CLN2 Mutations Causing Classical Late Infantile Neuronal Ceroid Lipofuscinosis Clin. Chem., October 1, 2000; 46(10): 1696 - 1699. [Full Text] [PDF]
|
|